Active Glycosylphosphatidylinositol Specific Phospholipase D1 (GPLD1) Homo sapiens (Human) Active protein

GPIPLD; GPIPLDM; PIGPLD; PIGPLD1; Glycoprotein phospholipase D; Glycosyl-phosphatidylinositol-specific phospholipase D

Add to Cart Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Point6.9
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Glycosylphosphatidylinositol Specific Phospholipase D1 (GPLD1) Packages (Simulation)
  • Active Glycosylphosphatidylinositol Specific Phospholipase D1 (GPLD1) Packages (Simulation)
  • APH975Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Glycosylphosphatidylinositol Specific Phospholipase D1 (GPLD1) is a secreted enzyme that cleaves glycosylphosphatidylinositol (GPI) anchors, releasing GPI-anchored proteins from cell membranes into circulation. Primarily synthesized in the liver, it plays key roles in lipid metabolism, inflammation, and neurogenesis. GPLD1's activity modulates the bioavailability of important GPI-anchored proteins like alkaline phosphatase and folate receptors. Studies link elevated GPLD1 levels to metabolic disorders and aging-related cognitive decline, while its neuroprotective effects are being investigated. The enzyme's structure contains catalytic domains essential for hydrolyzing GPI linkages, making it a potential therapeutic target for metabolic and neurological diseases.Besides,Alkaline Phosphatase, Tissue-nonspecific (ALPL) has been identified as an interactor of GPLD1, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human GPLD1 and recombinant human ALPL. Briefly, GPLD1 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to ALPL-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-GPLD1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human GPLD1 and recombinant human ALPL was shown in Figure 1, the EC50 for this effect is 0.042µg/mL.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Plasma glycosylphosphatidylinositol phospholipase D (GPI-PLD) and abdominal aortic aneurysmPubMed: PMC3443889
  • Serum glypican4 and glycosylphosphatidylinositol-specific phospholipase D levels are associated with adipose tissue insulin resistance in obese subjects with …Pubmed: 32816247

Recommend products